FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche said competition authorities should not allow the controlling shareholder of Novo Nordisk
to acquiring contract drug manufacturer Catalent
.
"It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available. From an industry perspective, it would be a wrong decision by authorities," Roche's CEO Thomas Schinecker said in a media call after the release of quarterly sales.
(Reporting by Ludwig Burger, Editing by Rachel More)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。